You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back

Relvar: a considerably lower carbon footprint than MDIs1

In this day and age, it’s important to be informed as to the environmental impact of the treatments we prescribe our patients.

That’s why we’re proud to say that, compared with other asthma devices, Relvar Ellipta has one of the lowest carbon footprints.1

Annual carbon footprints (kg CO2e) for different combinations of Relvar, Seretide and Ventolin and annual footprint reduction of different actions

annual carbon footprints graph

This graph has been independently created by GSK from the original data. The same results were first published in Janson C, et al. Thorax 2020;75:82–84.

Contribution of phases in the life cycle of different inhaler devices to their individual carbon footprint (net kg CO2e/per pack) and annual carbon footprints of each device

life cycle contributions graph

Discover Relvar


*If using on average two doses per day.


CO2e, annual carbon footprint; MDI, metered dose inhaler.

  1. Janson C, et al. Thorax [1] 2020;75:82–84.

RELVAR Ellipta was created in collaboration with

Innoviva logo

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Relvar is a registered trademark of the GlaxoSmithKline group of companies

PM-IE-FFV-WCNT-230009 June 2023